CL2014003372A1 - Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos - Google Patents

Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos

Info

Publication number
CL2014003372A1
CL2014003372A1 CL2014003372A CL2014003372A CL2014003372A1 CL 2014003372 A1 CL2014003372 A1 CL 2014003372A1 CL 2014003372 A CL2014003372 A CL 2014003372A CL 2014003372 A CL2014003372 A CL 2014003372A CL 2014003372 A1 CL2014003372 A1 CL 2014003372A1
Authority
CL
Chile
Prior art keywords
dual
antigen binding
receptor antagonist
binding proteins
antagonist antigen
Prior art date
Application number
CL2014003372A
Other languages
English (en)
Inventor
Han Huiquan
Zhou Xiaolan
Chen Qing
Tsai Mei-Mei
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2014003372A1 publication Critical patent/CL2014003372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2014003372A 2012-06-11 2014-12-11 Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos CL2014003372A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658237P 2012-06-11 2012-06-11
PCT/US2013/045245 WO2013188448A2 (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
CL2014003372A1 true CL2014003372A1 (es) 2015-04-10

Family

ID=49758865

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003372A CL2014003372A1 (es) 2012-06-11 2014-12-11 Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos

Country Status (21)

Country Link
US (5) US9453080B2 (es)
EP (3) EP3540070A1 (es)
JP (1) JP2015525230A (es)
KR (1) KR20150030706A (es)
CN (1) CN104540961A (es)
AU (1) AU2013274347B2 (es)
BR (1) BR112014031028A2 (es)
CA (1) CA2877669A1 (es)
CL (1) CL2014003372A1 (es)
CO (1) CO7240399A2 (es)
EA (1) EA201492282A1 (es)
HK (1) HK1208499A1 (es)
IL (1) IL236133A0 (es)
MA (1) MA37761A1 (es)
MX (1) MX2014015195A (es)
NZ (1) NZ703724A (es)
PE (1) PE20150642A1 (es)
PH (1) PH12014502754A1 (es)
SG (2) SG11201408228QA (es)
TN (2) TN2015000448A1 (es)
WO (1) WO2013188448A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014031028A2 (pt) * 2012-06-11 2017-08-15 Amgen Inc Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
PL2895503T3 (pl) 2012-09-13 2019-09-30 Bristol-Myers Squibb Company Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną
CA2969800A1 (en) * 2014-12-08 2016-06-16 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
GB201500464D0 (en) * 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
WO2017147182A1 (en) * 2016-02-22 2017-08-31 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
KR20230152153A (ko) 2016-03-10 2023-11-02 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018162931A1 (en) * 2017-03-10 2018-09-13 Ucl Business Plc Method relating to myostatin pathway inhibition
US11104737B2 (en) 2017-03-28 2021-08-31 Rigel Pharmaceuticals, Inc. ACVR2A-specific antibody and method of treatment of muscle atrophy
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
WO2020243448A1 (en) * 2019-05-30 2020-12-03 Acceleron Pharma Inc. Actrii-binding proteins and uses thereof
EP4121088A4 (en) * 2020-03-20 2024-07-03 Keros Therapeutics Inc METHODS OF USING ACTIVIN TYPE IIB RECEPTOR VARIANTS
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU4541093A (en) 1992-06-18 1994-01-24 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1278778A2 (en) 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
DK2332977T3 (en) * 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
WO2013106175A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
SG171813A1 (en) 2008-11-26 2011-07-28 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
MY153078A (en) * 2009-04-27 2014-12-31 Novartis Ag Compositions and methods for increasing muscle growth
US8524217B2 (en) * 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
BR112014031028A2 (pt) * 2012-06-11 2017-08-15 Amgen Inc Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置

Also Published As

Publication number Publication date
PH12014502754A1 (en) 2015-03-02
WO2013188448A2 (en) 2013-12-19
HK1208499A1 (en) 2016-03-04
PE20150642A1 (es) 2015-05-26
TN2014000513A1 (en) 2016-03-30
AU2013274347B2 (en) 2018-03-08
CA2877669A1 (en) 2013-12-19
EP2859114B1 (en) 2019-05-15
WO2013188448A8 (en) 2014-05-08
US20210340262A1 (en) 2021-11-04
US10981999B2 (en) 2021-04-20
MX2014015195A (es) 2015-02-17
AU2013274347A1 (en) 2015-02-05
NZ703724A (en) 2017-06-30
US20240327526A1 (en) 2024-10-03
MA37761A1 (fr) 2017-09-29
CN104540961A (zh) 2015-04-22
US20170107288A1 (en) 2017-04-20
EP2859114A4 (en) 2016-08-03
SG11201408228QA (en) 2015-01-29
EP3540070A1 (en) 2019-09-18
US20190256605A1 (en) 2019-08-22
IL236133A0 (en) 2015-01-29
CO7240399A2 (es) 2015-04-17
TN2015000448A1 (en) 2017-04-06
SG10201610356YA (en) 2017-01-27
KR20150030706A (ko) 2015-03-20
US9453080B2 (en) 2016-09-27
BR112014031028A2 (pt) 2017-08-15
EA201492282A1 (ru) 2015-07-30
EP3498857A1 (en) 2019-06-19
US10266598B2 (en) 2019-04-23
US20150152194A1 (en) 2015-06-04
WO2013188448A3 (en) 2014-04-10
EP2859114A2 (en) 2015-04-15
JP2015525230A (ja) 2015-09-03

Similar Documents

Publication Publication Date Title
CL2014003372A1 (es) Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos
DK2997134T3 (da) Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
HK1212711A1 (zh) 抗原結合蛋白
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
DK2850103T3 (da) ST2-antigenbindende proteiner
DK2935326T3 (da) Humane anti-tau-antistoffer
DK2934584T3 (da) Anti-gdf15-antistoffer
DK2970464T3 (da) Anti-lag-3-bindende proteiner
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112015003838A2 (pt) formulações de anticorpo e proteína
DK2850101T3 (da) Anti-FcRn-antistoffer
CL2015000097A1 (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos.
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
DK2858676T3 (da) Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
BR112014019459A2 (pt) proteínas de ligação à cdim e usos das mesmas
HK1224310A1 (zh) 制瘤素 受體抗原結合蛋白
BR112013030352A2 (pt) proteínas de ligação do receptor fc
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer